Entecavir

Abstract

In March 2005, entecavir (Baraclude; Bristol-Myers Squibb) was approved by the US FDA for the treatment of hepatitis B virus (HBV) infection. It is the most potent inhibitor of the HBV DNA polymerase to be approved so far. 
DOI: 10.1038/nrd1780

Topics

1 Figure or Table

Cite this paper

@article{Opio2005Entecavir, title={Entecavir}, author={Christopher Kenneth Opio and William M. Lee and Peter John Kirkpatrick}, journal={Nature Reviews Drug Discovery}, year={2005}, volume={4}, pages={535-536} }